The transformation of the pharmaceutical industry in Cologne temporarily does not consider the expansion

Cologne Pharmaceutical Industry (002422.　　SZ) released its 2010 annual report late yesterday, and in 2010 the company realized its operating income of 4.026 billion yuan, an increase of 24.02% from a year earlier, and a net profit of 661 million yuan for the parent company's shareholders, which grew 54.55% from a year earlier.　　2010, the company's operating income of 4.026 billion yuan, an increase of 24.04%, the earnings per share of 3.08 yuan. Analysis of the company's annual report pointed out that, during the reporting period, the relatively high gross margin of soft plastic packaging injection product sales accounted for a year-on-year increase in the overall gross margin rise.　　At the same time, the company has effectively controlled the growth of cost and period cost in the case of fast growth of operating income, so that the net profit growth rate is greater than the growth of operating income.　　As a national infusion faucet, the main business in 2010, Cologne large-capacity injection agent income growth of 22.26%, not large-capacity injections than a year earlier growth of 44.18%.　　In its promotion of product upgrade transformation, the production of soft plastic packaging varieties increased by 54.7% over the previous year, has greatly exceeded the packaging production of glass bottles. The annual report pointed out that the new medical reform policy gradually promote the operating pressure will become apparent-one of the biggest bright spot of the new health reform is the improvement of the health care system brought the expansion of the medical market and the network sinking, the hospital drug purchase amount showed an increase in the momentum. However, from the perspective of national distribution, the existing production, sales and operation of distribution systems will also be broken by the implementation of the basic drug system.　　The network subsidence has put forward the great challenge to the pharmaceutical industry business cooperation mode and the commercial survival development. Cologne Pharmaceutical Chairman Liu Genue in the "two sessions" during the "first financial daily" interview, said, for the Chinese Medicine, China Resources and other central enterprises to accelerate the national expansion of the acquisition, currently, the Cologne has not been to the southwest market expansion of the idea, temporarily not with the former two positive contact.